News Focus
News Focus
icon url

tony111

02/05/24 9:54 PM

#250520 RE: DewDiligence #250519

25M for tafasitamab is a pretty good deal. Consider if tafasitamab is successful in first line DLBCL and second line lymphoma, INCY will have to pay MOR 500M in milestone.